Equateq in the Press

EQUATEQ'S OFFERINGS

EQUATEQ NEWS

Maxomega-90: A 'Blank Canvas' for Omega Oil Formulators

High-end Nutraceutical companies can now provide their customers with almost any ratio of EPA and DHA omega oil concentrates they want, with the launch of Maxomega-90...

ATTENDING

Stand 5D94, 5-7 October 2010

EQUATEQ VIDEO

See how Omega oils are made in the Western Isles

See video

Maxomega-90: A 'Blank Canvas' for Omega Oil Formulators, May. 7, 2010

High-end Nutraceutical companies can now provide their customers with almost any ratio of EPA and DHA omega oil concentrates they want, with the launch of Maxomega-90, a range that exploits pharmaceutical sector separation methods to deliver omega-3 EPA and DHA in any 90% combination, Equateq announced today.

‘We say that Maxomega-90 is like a blank canvas, allowing companies to mix lipid actives in almost any combination they require,’ explained Equateq CEO Adam Kelliher . 'This will enable companies to define their product rationale and give a more clear, and focused offering.'

Lipid specialist Equateq is unique in using industrial-scale chromotography to make lipid concentrates, in preference to the usual industry method of distillation. The Maxomega™ process can separate all key lipids at up to 99% purity, but these super-high levels are most used by pharmaceutical companies and researchers. The Maxomega-90 range is geared for the nutritional sector, allowing delivery of EPA and DHA in any ratio, from 80/10 to 10/80, with each offering always having at least 90% total omega-3.

Companies can formulate products based on the particular area they are targeting. For example, an EPA-rich 80/10 product could be made for this lipid's known anti-inflammatory properties. A DHA-rich 10/80 could be used for maintaining brain function. Or a 45/45 could deliver a balance of both EPA and DHA. Equateq can also concentrate other fatty acids, such as omega-6 GLA, so the Maxomega-90 strategy is not just confined to omega-3.

All production is done at Equateq's plant in the Western Isles of Scotland, under cGMP conditions, and the oils are delivered in Ethyl Ester form. Pricing is determined by the volume and the fatty acids being targed, and will be competitive. Equateq says it is confident that the Maxomega-90 will give great advantages to the sector.

'The Maxomega-90 ranges offers a great opportunity for any company that wants to claim the top spot in the omega oil space with defined formulations, and the highest production standards on offer,' Kelliher said. 'We think these can provide much-needed clarity in an increasingly cluttered marketplace.'

Equateq will be showcasing the Maxomega-90 range at Vitafoods (Stand 128) and in the New Product Zone:

Maxomega Range.jpg

For further enquiries, please contact: Rachel Malaney.

Omega Actives for Active People: Equateq Launches Whey-O3 - Dec. 5, 2009

The dual-benefits of Whey-protein and concentrated Omega-3 fish oils can now be enjoyed in a unique combination product with the launch of Whey-O3 today.

Pure, Potent and Natural Omega Oils: Equateq's Crystalpure™ Range Launched - Apr. 22, 2009

Customers in the omega oils sector can now use concentrates that are truly natural and bioavailable, with the launch of Equateq's Crystalpure™ Range.

Equateq bullish about lipid API Market - Aug. 27, 2008

Equateq CEO Adam Kelliher is interviewed about the state of the lipid API Market for Pharmatechnologist Magazine

Equateq Facility Certified for GMP Pharma Production - Aug. 22, 2008

The fatty acid concentration plant run by Equateq in the Western Isles of Scotland has been certified as GMP compliant by Britain’s healthcare authority, giving it the necessary credentials to produce high-end lipid compounds as active pharmaceutical ingredients for the booming omega oils sector, the company announced Friday.

Equateq opens super omega-3 factory in Scotland - Aug 25, 2007

A production and research facility able to make super-pure fatty acid concentrates for the nutrition industry has officially opened in the Western Isles of Scotland with the potential to offer gold standard omega-3.

Pioneer's daughter to reopen Isles factory - Aug. 23, 2007

A FACTORY on Lewis set up by the medical pioneer David Horrobin will be reopened this week by his daughter.

The final frontier for fatty acids - Aug. 20, 2007

A new facility has opened in the Western Isles of Scotland boasting a unique two-stage process for making fatty acid concentrates of up to 99% purity from marine or botanical oils.